376 related articles for article (PubMed ID: 35116092)
21. Role of Iron in the Molecular Pathogenesis of Diseases and Therapeutic Opportunities.
Abbasi U; Abbina S; Gill A; Takuechi LE; Kizhakkedathu JN
ACS Chem Biol; 2021 Jun; 16(6):945-972. PubMed ID: 34102834
[TBL] [Abstract][Full Text] [Related]
22. Canonical Wnt signaling in diabetic retinopathy.
Chen Q; Ma JX
Vision Res; 2017 Oct; 139():47-58. PubMed ID: 28545982
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic Macromolecular Iron Chelators.
Bulbake U; Singh A; Domb AJ; Khan W
Curr Med Chem; 2019; 26(2):323-334. PubMed ID: 30182850
[TBL] [Abstract][Full Text] [Related]
24. Iron chelating strategies in systemic metal overload, neurodegeneration and cancer.
Gumienna-Kontecka E; Pyrkosz-Bulska M; Szebesczyk A; Ostrowska M
Curr Med Chem; 2014; 21(33):3741-67. PubMed ID: 25005181
[TBL] [Abstract][Full Text] [Related]
25. Molecular targets and therapeutic interventions for iron induced neurodegeneration.
Bagwe-Parab S; Kaur G
Brain Res Bull; 2020 Mar; 156():1-9. PubMed ID: 31866454
[TBL] [Abstract][Full Text] [Related]
26. Effect of iron chelators on labile iron and oxidative status of thalassaemic erythroid cells.
Prus E; Fibach E
Acta Haematol; 2010; 123(1):14-20. PubMed ID: 19923794
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic potential of iron chelators in diseases associated with iron mismanagement.
Weinberg ED
J Pharm Pharmacol; 2006 May; 58(5):575-84. PubMed ID: 16640825
[TBL] [Abstract][Full Text] [Related]
28. The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma.
Kamihara Y; Takada K; Sato T; Kawano Y; Murase K; Arihara Y; Kikuchi S; Hayasaka N; Usami M; Iyama S; Miyanishi K; Sato Y; Kobune M; Kato J
Oncotarget; 2016 Sep; 7(39):64330-64341. PubMed ID: 27602957
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload.
Wu D; Wen X; Liu W; Hu H; Ye B; Zhou Y
Drug Des Devel Ther; 2018; 12():1081-1091. PubMed ID: 29760547
[TBL] [Abstract][Full Text] [Related]
30. Current and future treatment strategies for iron overload cardiomyopathy.
Wongjaikam S; Kumfu S; Chattipakorn SC; Fucharoen S; Chattipakorn N
Eur J Pharmacol; 2015 Oct; 765():86-93. PubMed ID: 26291660
[TBL] [Abstract][Full Text] [Related]
31. Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity.
Jiménez-Solas T; López-Cadenas F; Aires-Mejía I; Caballero-Berrocal JC; Ortega R; Redondo AM; Sánchez-Guijo F; Muntión S; García-Martín L; Albarrán B; Alonso JM; Del Cañizo C; Hernández-Hernández Á; Díez-Campelo M
Br J Haematol; 2019 Oct; 187(1):93-104. PubMed ID: 31172513
[TBL] [Abstract][Full Text] [Related]
32. Treating iron overload: the state of the art.
Hershko C
Semin Hematol; 2005 Apr; 42(2 Suppl 1):S2-4. PubMed ID: 15846582
[No Abstract] [Full Text] [Related]
33. Effects of Iron Chelators on Pulmonary Iron Overload and Oxidative Stress in β-Thalassemic Mice.
Yatmark P; Morales NP; Chaisri U; Wichaiyo S; Hemstapat W; Srichairatanakool S; Svasti S; Fucharoen S
Pharmacology; 2015; 96(3-4):192-9. PubMed ID: 26316149
[TBL] [Abstract][Full Text] [Related]
34. Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine.
Pennell DJ; Porter JB; Piga A; Lai YR; El-Beshlawy A; Elalfy M; Yesilipek A; Kilinç Y; Habr D; Musallam KM; Shen J; Aydinok Y;
Am J Hematol; 2015 Feb; 90(2):91-6. PubMed ID: 25345697
[TBL] [Abstract][Full Text] [Related]
35. Deferasirox for transfusion-related iron overload: a clinical review.
Lindsey WT; Olin BR
Clin Ther; 2007 Oct; 29(10):2154-66. PubMed ID: 18042472
[TBL] [Abstract][Full Text] [Related]
36. Deferasirox.
Stumpf JL
Am J Health Syst Pharm; 2007 Mar; 64(6):606-16. PubMed ID: 17353569
[TBL] [Abstract][Full Text] [Related]
37. Iron mobilization using chelation and phlebotomy.
Flaten TP; Aaseth J; Andersen O; Kontoghiorghes GJ
J Trace Elem Med Biol; 2012 Jun; 26(2-3):127-30. PubMed ID: 22565013
[TBL] [Abstract][Full Text] [Related]
38. Deferasirox for managing iron overload in people with thalassaemia.
Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
Cochrane Database Syst Rev; 2012 Feb; (2):CD007476. PubMed ID: 22336831
[TBL] [Abstract][Full Text] [Related]
39. TLc-A, the leading nanochelating-based nanochelator, reduces iron overload in vitro and in vivo.
Kalanaky S; Hafizi M; Safari S; Mousavizadeh K; Kabiri M; Farsinejad A; Fakharzadeh S; Nazaran MH
Int J Hematol; 2016 Mar; 103(3):274-82. PubMed ID: 26830968
[TBL] [Abstract][Full Text] [Related]
40. An update on disordered iron metabolism and iron overload.
Ward R
Hematology; 2010 Oct; 15(5):311-7. PubMed ID: 20863426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
